Illustrative biotech sample. Paid orders deliver a full 10–20 page professional multi-section PDF with multi-source collection. Not legal or financial advice.
Screening a real biotech target? Same layout, live multi-source PDF — $49 after Stripe.
Order $39.20 →| Asset | CDMO | Function | Status | Open issue |
|---|---|---|---|---|
| HLX-204 drug substance | Lonza · Visp | API | FDA obs. | Observation 483 outstanding; remediation in progress |
| HLX-204 drug product | Patheon · Milano | Fill / finish | Clean | Capacity reserved through Phase 3 launch |
| HLX-118 back-up | Samsung Biologics | API (secondary) | Contracting | Tech transfer Q1 FY27 pending partner opt-in |
| HLX-310 preclinical | Catalent · Indiana | Preclinical tox supply | Clean | None material; small-molecule, off-the-shelf CDMO |
| Companion diagnostic | Foundation Medicine (Roche) | PIK3CA mutation panel | Validation | Validation locked to HLX-204 interim; may need orthogonal second assay |
Single-source API on the lead asset is the highest-m materiality CMC risk — second-source agreement is the gating item before any term sheet.
| Burn scenario | Quarterly burn | FY26E year-end cash | Runway through | Probability (mgmt commentary) |
|---|---|---|---|---|
| Base (flat opex) | $22M | $220M | Q2 FY28 | 55% |
| Up (Ph3 enable + 25% headcount) | $31M | $184M | Q4 FY27 | 25% |
| Down (defer HLX-310 IND 12 mo) | $17M | $240M | Q4 FY28 | 15% |
| Bull (partner opt-in Q4 FY26) | $9M | $300M+ cash + $40M inflow | FY29+ | 30% |
If management hits a sub-50% runway scenario without bridging capital, dilution or restructured partner economics is required before the HLX-204 interim readout.
| Date | Event | Asset | Materiality | Possible re-rating |
|---|---|---|---|---|
| Q3 FY26 | Interim Phase 2 ORR (n=92) | HLX-204 | High | ±35–50% on clean / dirty read |
| Q4 FY26 | FDA Type-B meeting | HLX-204 | Medium | +10–15% on accelerated path |
| Q1 FY27 | Pfizer opt-in deadline | HLX-118 | Medium | $40M inflow baseline, $300M+ bull |
| Q2 FY27 | IND filing | HLX-310 | Low | Re-rates pipeline breadth, not single-event |
| Q3 FY27 | Phase 2 primary endpoint | HLX-204 | High | ±60% on clean / fail |
| Date | Target / Deal | Stage | Headline value | Multiple / term | Relevance to HLXT |
|---|---|---|---|---|---|
| 2024-Q4 | Mirati acquisition by BMY | Phase 2 allosteric platform | $4.8B EV | 38% premium-to-unaffected | Same allosteric pocket class — anchor on success |
| 2025-Q2 | Relay / J&J option (PI3Kα) | Phase 1 option-to-acquire | $130M upfront | $800M milestones undisclosed | Direct PI3Kα platform comp — read on partner appetite |
| 2025-Q3 | Black Diamond Series C | Mid-cap oncology platform | $135M raised | 30% premium-to-trough | Crossover / PIPE pricing reference |
| 2026-Q1 | RayzeBio (BMY) | Radiopharma, late preclinical | $4.1B EV | Cash, no milestones | Adjacent modality M&A read |
Life-sciences PE/VC first pass: cash runway, pipeline concentration, CMC/reg flags, catalyst calendar — before counsel hours.
Get this on your target →Sample tags only. Live packs attach public-source citations and severity notes; not a medical or investment opinion.
| Decision | Trigger | Pre-condition to override | Sample HLXT read |
|---|---|---|---|
| Kill | Runway < 12 mo and no non-dilutive path | Signed bridge / partner term sheet ≥ 18 mo | Cash 14 mo, no signed path → Hold pending readout |
| Kill | Fatal CMC / clinical hold on lead asset | Mitigation plan ≤ 60 days with second-source agreement | Lonza observation open; second-source not yet signed |
| Hold | Concentration > 70% NPV in one readout | Dual-asset NPV plan w/ IND filing on second program | 71% on HLX-204; HLX-310 IND expected Q2 FY27 |
| Hold | Contested core IP without FTO memo | EPO opposition RSS resolution + counsel memo | Relay opposition filed; medium materiality until RSS |
| Go | Cash > 18 mo · dual-source · clean interim ORR band | — (positive state) | Cash base = 14 mo; not yet Go criteria |
Biotech PE lens: runway · concentration · CMC/reg · catalyst calendar · kill-gates — before counsel hours. PDF delivery · DI20-WELCOME.
Order $39.20 →Post-close value creation in biotech pharma deals hinges on pipeline economics, CMC scale-up, and platform leverage. Below is the illustrative framework our packs surface with public signals.
| Lever | Thesis | Public signal | Quantification potential |
|---|---|---|---|
| Pipeline acceleration | Fund lead asset through Ph2 readout with sponsor cash | Trial registry enrollment velocity; cash runway vs catalyst timeline | +12–18 months optionality vs partnership dilution |
| CMC / manufacturing scale-up | Move from CDMO to internal GMP line post-close | CDMO vs internal: job posts, facility filings, FDA inspections | ~$4–8M annual COGS reduction at commercial scale |
| Platform re-use | Apply delivery tech to portfolio company pipeline | Patent claims; platform publications; modality breadth | 2–3 new asset starts per platform cycle (internal valuation) |
| Indication expansion | Pursue orphan → broader label strategy | FDA orphan designations; competitive landscape in adjacent indications | $30–80M peak sales per added orphan indication |
| BD&L monetisation | Out-license non-core assets or regional rights | Pipeline depth; competitive programs at same stage | $5–15M upfront + milestones per regional deal |
| Regulatory strategy | Fast track / breakthrough / RMAT designation | FDA meeting history; surrogate endpoint precedent | 6–12 month approval timeline compression |
| G&A / infrastructure | Centralise clinical ops, biostats, regulatory across portfolio | Headcount ratios vs clinical-stage peers; CRO vs internal | ~$2–4M annual savings (shared services model) |
Why this matters: Biotech IC memos trade on probability-weighted NPV and catalyst timing. Showing each lever with public signals (trial velocity, CMC readiness, regulatory precedent) signals scientific seriousness to the deal team. Order on your target →
Clinical-stage biotech underwriting is a cash + probability problem. This bridge shows how associates restate "headline runway" before IC.
| Line | Reported / claim | Adjustment | Adjusted | Public signal |
|---|---|---|---|---|
| Cash & equivalents | $48.2M | −$3.1M restricted / escrow | $45.1M | 10-Q cash note; restricted cash footnote |
| Net quarterly burn | $9.4M | +$1.8M one-time CMC deposit add-back reversed | $11.2M | Cash flow + CDMO contract milestones |
| Runway (months) | 15.4 | −3.2 mo (burn restatement) | ~12.2 | Cash / restated burn; no new financing assumed |
| R&D (mgmt view) | $28.6M TTM | −$2.4M capitalized CMC reclass challenged | $31.0M expense-like | R&D note vs peer expense ratios |
| Partner / grant cash | $6.0M committed | −$4.0M contingent on readout | $2.0M near-certain | Collaboration agreement opt-in language |
Live pack: auto-flags runway cliffs against catalyst dates so you walk into QoE / rNPV with a pre-built challenge list. Order on your target →
Mirrors the management section of the live multi-section PDF. Ask these before LOI; escalate red answers into SPA / escrow protections.
| # | Question | Why it matters | Red answer |
|---|---|---|---|
| 1 | Who is the named IND/NDA holder, and are all inventors / prior employers assigned? | IP ownership chain (see also /ip-due-diligence) | Unassigned inventors; university claim not settled |
| 2 | Walk the last FDA/EMA interaction outcomes and any complete-response history. | Regulatory path credibility | Unresolved CMC hold; no minutes available |
| 3 | Show CDMO dual-source plan and tech-transfer cost/timeline for drug substance. | Single-point manufacturing risk | One CDMO only; 18+ month re-qual; no inventory buffer |
| 4 | What % of enterprise value is in the lead asset vs platform optionality? | Concentration of scientific risk | >90% NPV in one unpartnered program with binary readout |
| 5 | Board composition, related-party CROs, and any founder consulting above market. | Governance / leakage into burn | Related-party CRO at premium; no competitive bid |
| 6 | Hiring plan for clinical ops / biostats vs open reqs and CRO dependency. | Execution capacity into readout | Key biostats contractor only; no internal backup |
| 7 | Disclose open IP litigation, freedom-to-operate opinions, and Orange Book risks. | Contingent legal / FTO | No FTO memo; competitor patent thicket ignored |
| 8 | How are partner opt-in, change-of-control, and clawback clauses structured? | Deal structure / exit flexibility | Partner consent required on change of control with veto |
Why this depth: samples that only show narrative lose buyers. Live packs include governance questions + risk register so associates leave with an IC-ready workplan. Get the full PDF on your target → · 100+ DD questions guide · Healthcare PE guide